Related references
Note: Only part of the references are listed.In-/off-label use of biologic therapy in systemic lupus erythematosus
Mariele Gatto et al.
BMC MEDICINE (2014)
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
M. Joerger et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Off-label drug use in hospitals
Imma Danes et al.
MEDICINA CLINICA (2014)
Incidence of unlicensed and off-label prescription in children
Petra Langerova et al.
ITALIAN JOURNAL OF PEDIATRICS (2014)
Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital
Jennifer R. Bellis et al.
BMC MEDICINE (2013)
Available evidence and outcome of off-label use of rituximab in clinical practice
I. Danes et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Experience with low-dose rituximab in off-label indications at two tertiary hospitals
J. Chay et al.
INTERNAL MEDICINE JOURNAL (2013)
Prospective data collection of off-label use of rituximab in Australian public hospitals
K. O'Connor et al.
INTERNAL MEDICINE JOURNAL (2013)
FDA Regulation of Off-label Drug Promotion Under Attack
Aaron S. Kesselheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Marcus Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Prescriptions hors-AMM : comment en pratique les identifier, les encadrer, informer et les suivre ?
Claire Le Jeunne et al.
THERAPIE (2013)
Drug, Patient, and Physician Characteristics Associated With Off-label Prescribing in Primary Care
Tewodros Eguale et al.
ARCHIVES OF INTERNAL MEDICINE (2012)
Japanese Regulatory System for Approval of Off-Label Drug Use: Evaluation of Safety and Effectiveness in Literature-Based Applications
Rumiko Shimazawa et al.
CLINICAL THERAPEUTICS (2012)
Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme
J. D. Mellor et al.
INTERNAL MEDICINE JOURNAL (2012)
The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
Aaron S. Kesselheim et al.
PLOS ONE (2012)
Free speech rights outweigh restrictions on promoting drugs off label, court rules
Bob Roehr
BMJ-BRITISH MEDICAL JOURNAL (2012)
Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
Loreto Carmona et al.
RHEUMATOLOGY (2011)
Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol
Belen Ruiz-Antoran et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Systematic review and meta-analysis of randomized controlled trials comparing botulinum toxin injection with lateral internal sphincterotomy for chronic anal fissure
Wan-Jin Shao et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature
L. Lindell-Osuagwu et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
Botulinum toxin vs glyceryltrinitrate for the medical management of chronic anal fissure:: a meta-analysis
M. S. Sajid et al.
COLORECTAL DISEASE (2008)
Off-label prescribing among office-based physicians
David C. Radley et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Risk factors for unlicensed and off-label drug use in children outside the hospital
E Schirm et al.
PEDIATRICS (2003)
Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands
GW 't Jong et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Share Paper
